EZH2 is altered in 19.08% of follicular lymphoma patients [3].

EZH2 is an inclusion criterion in 3 clinical trials for follicular lymphoma, of which 2 are open and 1 is closed. Of the trials that contain EZH2 status and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

Tazemetostat has evidence of efficacy in patients with EZH2 mutation in follicular lymphoma [4].

EZH2 is altered in 1.19% of malignant solid tumor patients [3].

EZH2 is an inclusion criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain EZH2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

EZH2 is altered in 5.77% of myelodysplastic syndromes patients [3].

EZH2 is an inclusion criterion in 4 clinical trials for myelodysplastic syndromes, of which 4 are open and 0 are closed. Of the trials that contain EZH2 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

EZH2 is altered in 3.38% of acute myeloid leukemia patients [3].

EZH2 is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain EZH2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

EZH2 is altered in 11.53% of diffuse large B-cell lymphoma patients [3].

EZH2 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain EZH2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

EZH2 is altered in 8.16% of chronic myelomonocytic leukemia patients [3].

EZH2 is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain EZH2 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

EZH2 is altered in 8.7% of non-hodgkin lymphoma patients [3].

EZH2 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EZH2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

EZH2 is altered in 7.23% of secondary acute myeloid leukemia patients [3].

EZH2 is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain EZH2 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

EZH2 is altered in 3.48% of melanoma patients [3].

EZH2 is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain EZH2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

EZH2 is altered in 0.41% of multiple myeloma patients [3].

EZH2 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 0 are open and 2 are closed. Of the trials that contain EZH2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

EZH2 is altered in 10.8% of B-cell non-hodgkin lymphoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

EZH2 is altered in 7.61% of lymphoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 7.23% of therapy-related acute myeloid leukemia patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

EZH2 is altered in 6.06% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

EZH2 is altered in 7.83% of myelofibrosis patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

EZH2 is altered in 7.12% of myelodysplastic/myeloproliferative neoplasm patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

EZH2 is altered in 4.23% of therapy-related myelodysplastic syndrome patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

EZH2 is altered in 3.2% of myelodysplastic syndrome with excess blasts-2 patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is altered in 4.3% of myeloid neoplasm patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is altered in 1.58% of anaplastic astrocytoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 1.16% of malignant peripheral nerve sheath tumor patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is altered in 1.31% of bladder carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 1.21% of colorectal carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 1.46% of glioblastoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 1.19% of head and neck carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is altered in 0.96% of non-small cell lung carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 0.93% of ovarian carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 0.89% of breast carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 0.75% of sarcoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is altered in 0.48% of pancreatic carcinoma patients [3].

EZH2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

EZH2 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

EZH2 is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and epithelioid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

EZH2 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and rhabdoid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

EZH2 is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and synovial sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].